Literature DB >> 18042431

How does HTLV-I persist despite a strong cell-mediated immune response?

Becca Asquith1, Charles R M Bangham.   

Abstract

Human T-lymphotropic virus type 1 (HTLV-1) is a pathogenic retrovirus that infects human CD4(+) T lymphocytes. Despite its presence in T cells, HTLV-1 causes little overt immunosuppression. This host-virus relationship has therefore been exploited as an excellent model system for studying the dynamic interaction between a persistent retrovirus and the normal human immune system. We use a combination of mathematical and experimental techniques to identify key factors on both sides of the in vivo host-virus interaction that significantly determine HTLV-I proviral load and disease risk. We develop a model to describe how these factors interact to enable viral persistence.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18042431      PMCID： PMC6066088          DOI： 10.1016/j.it.2007.09.006

Source DB:  PubMed          Journal:  Trends Immunol        ISSN： 1471-4906            Impact factor:   16.687


  61 in total

1.  Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP.

Authors:  M Nagai; K Usuku; W Matsumoto; D Kodama; N Takenouchi; T Moritoyo; S Hashiguchi; M Ichinose; C R Bangham; S Izumo; M Osame
Journal:  J Neurovirol       Date:  1998-12       Impact factor: 2.643

2.  A comparison of two techniques for the molecular tracking of specific T-cell responses; CD4+ human T-cell clones persist in a stable hierarchy but at a lower frequency than clones in the CD8+ population.

Authors:  M K Maini; L R Wedderburn; F C Hall; A Wack; G Casorati; P C Beverley
Journal:  Immunology       Date:  1998-08       Impact factor: 7.397

3.  HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy.

Authors:  K J Jeffery; K Usuku; S E Hall; W Matsumoto; G P Taylor; J Procter; M Bunce; G S Ogg; K I Welsh; J N Weber; A L Lloyd; M A Nowak; M Nagai; D Kodama; S Izumo; M Osame; C R Bangham
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

4.  Regression of human T-cell leukemia virus type I (HTLV-I)-associated lymphomas in a rat model: peptide-induced T-cell immunity.

Authors:  S Hanabuchi; T Ohashi; Y Koya; H Kato; A Hasegawa; F Takemura; T Masuda; M Kannagi
Journal:  J Natl Cancer Inst       Date:  2001-12-05       Impact factor: 13.506

5.  Molecular evolution of human T-cell leukemia virus.

Authors:  Y Ina; T Gojobori
Journal:  J Mol Evol       Date:  1990-12       Impact factor: 2.395

6.  HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes.

Authors:  K L Collins; B K Chen; S A Kalams; B D Walker; D Baltimore
Journal:  Nature       Date:  1998-01-22       Impact factor: 49.962

7.  Persistent clonal proliferation of human T-lymphotropic virus type I-infected cells in vivo.

Authors:  K Etoh; S Tamiya; K Yamaguchi; A Okayama; H Tsubouchi; T Ideta; N Mueller; K Takatsuki; M Matsuoka
Journal:  Cancer Res       Date:  1997-11-01       Impact factor: 12.701

8.  Protective efficacy of multiepitope human leukocyte antigen-A*0201 restricted cytotoxic T-lymphocyte peptide construct against challenge with human T-cell lymphotropic virus type 1 Tax recombinant vaccinia virus.

Authors:  Roshni Sundaram; Marcus P Lynch; Sharad Rawale; Naveen Dakappagari; Donn Young; Christopher M Walker; Francois Lemonnier; Steven Jacobson; Pravin T P Kaumaya
Journal:  J Acquir Immune Defic Syndr       Date:  2004-11-01       Impact factor: 3.731

9.  In vivo T lymphocyte dynamics in humans and the impact of human T-lymphotropic virus 1 infection.

Authors:  Becca Asquith; Yan Zhang; Angelina J Mosley; Catherine M de Lara; Diana L Wallace; Andrew Worth; Lambrini Kaftantzi; Kiran Meekings; George E Griffin; Yuetsu Tanaka; David F Tough; Peter C Beverley; Graham P Taylor; Derek C Macallan; Charles R M Bangham
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-01       Impact factor: 11.205

10.  Genetic stability of human T lymphotropic virus type I despite antiviral pressures by CTLs.

Authors:  Ryuji Kubota; Kousuke Hanada; Yoshitaka Furukawa; Kimiyoshi Arimura; Mitsuhiro Osame; Takashi Gojobori; Shuji Izumo
Journal:  J Immunol       Date:  2007-05-01       Impact factor: 5.422
View more
  19 in total

1.  Presentation of human T cell leukemia virus type 1 (HTLV-1) Tax protein by dendritic cells: the underlying mechanism of HTLV-1-associated neuroinflammatory disease.

Authors:  Sharrón L Manuel; Todd D Schell; Edward Acheampong; Saifur Rahman; Zafar K Khan; Pooja Jain
Journal:  J Leukoc Biol       Date:  2009-08-05       Impact factor: 4.962

2.  A statistical model for genetic mapping of viral infection by integrating epidemiological behavior.

Authors:  Yao Li; Arthur Berg; Myron N Chang; Ping Du; Kwangmi Ahn; David Mauger; Duanping Liao; Rongling Wu
Journal:  Stat Appl Genet Mol Biol       Date:  2009-09-09

3.  The host genomic environment of the provirus determines the abundance of HTLV-1-infected T-cell clones.

Authors:  Nicolas A Gillet; Nirav Malani; Anat Melamed; Niall Gormley; Richard Carter; David Bentley; Charles Berry; Frederic D Bushman; Graham P Taylor; Charles R M Bangham
Journal:  Blood       Date:  2011-01-12       Impact factor: 22.113

4.  Long-term persistence of limited HTLV-I Tax-specific cytotoxic T cell clones in a patient with adult T cell leukemia/lymphoma after allogeneic stem cell transplantation.

Authors:  Yukie Tanaka; Hideki Nakasone; Rie Yamazaki; Hidenori Wada; Yuko Ishihara; Koji Kawamura; Kana Sakamoto; Masahiro Ashizawa; Tomohito Machishima; Miki Sato; Kiriko Terasako; Shun-ichi Kimura; Misato Kikuchi; Shinya Okuda; Shinichi Kako; Junya Kanda; Aki Tanihara; Junji Nishida; Yoshinobu Kanda
Journal:  J Clin Immunol       Date:  2012-07-05       Impact factor: 8.317

5.  Immune activation induces immortalization of HTLV-1 LTR-Tax transgenic CD4+ T cells.

Authors:  Alison Y Swaims; Francesca Khani; Yingyu Zhang; Arthur I Roberts; Satish Devadas; Yufang Shi; Arnold B Rabson
Journal:  Blood       Date:  2010-07-15       Impact factor: 22.113

6.  Cyclosporine-induced immune suppression alters establishment of HTLV-1 infection in a rabbit model.

Authors:  Rashade A H Haynes; Evan Ware; Christopher Premanandan; Bevin Zimmerman; Lianbo Yu; Andrew J Phipps; Michael D Lairmore
Journal:  Blood       Date:  2009-11-20       Impact factor: 22.113

7.  Adaptive immune response to viral infections in the central nervous system.

Authors:  Jane E Libbey; Robert S Fujinami
Journal:  Handb Clin Neurol       Date:  2014

8.  Different roles of CXCR1 and CXCR2 in HTLV-1 carriers and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients.

Authors:  Taraneh Rajaei; Hamid Farajifard; Seyed Abdolrahim Rezaee; Mahmoud Reza Azarpazhooh; Mahmoud Mahmoudi; Narges Valizadeh; Houshang Rafatpanah
Journal:  Med Microbiol Immunol       Date:  2018-10-20       Impact factor: 3.402

9.  IFN-gamma production in response to Tax 161-233, and frequency of CD4+ Foxp3+ and Lin HLA-DRhigh CD123+ cells, discriminate HAM/TSP patients from asymptomatic HTLV-1-carriers in a Peruvian population.

Authors:  Ivan Best; Giovanni López; Kristien Verdonck; Elsa González; Martín Tipismana; Eduardo Gotuzzo; Guido Vanham; Daniel Clark
Journal:  Immunology       Date:  2009-02-17       Impact factor: 7.397

Review 10.  Mechanisms of HTLV-1 persistence and transformation.

Authors:  M Boxus; L Willems
Journal:  Br J Cancer       Date:  2009-09-29       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.